Novel insights into Tim-4 function in autoimmune diseases

References

• Rodriguez-Manzanet, R., R. DeKruyff, V. K. Kuchroo, and D. T. Umetsu. 2009. The costimulatory role of TIM molecules. Immunol. Rev. 229: 259–270
   PubMed Web of Science ®Google Scholar
• Kane, L. P. 2007. TIM family proteins and autoimmunity. Autoimmunity 40: 405–408
   PubMed Web of Science ®Google Scholar
• Li, Z., Z. Ju, and M. Frieri. 2013. The T-cell immunoglobulin and mucin domain (Tim) gene family in asthma, allergy, and autoimmunity. Allergy Asthma Proc. 34: e21–26
   Web of Science ®Google Scholar
• Khademi, M., Z. Illes, A. W. Gielen, et al. 2004. T Cell Ig- and mucin-domain-containing molecule-3 (TIM-3) and TIM-1 molecules are differentially expressed on human Th1 and Th2 cells and in cerebrospinal fluid-derived mononuclear cells in multiple sclerosis. J. Immunol. 172: 7169–7176
   PubMed Web of Science ®Google Scholar
• Nozaki, Y., A. R. Kitching, H. Akiba, et al. 2014. Endogenous Tim-1 promotes severe systemic autoimmunity and renal disease MRL-Fas (lpr) mice. Am. J. Physiol. Renal. Physiol. 306: F1210–F1221
   PubMedGoogle Scholar
• Kawamoto, T., Y. Abe, J. Ito, et al. 2011. Anti-T cell immunoglobulin and mucin domain-2 monoclonal antibody exacerbates collagen-induced arthritis by stimulating B cells. Arthritis Res. Ther. 13: R47
   Google Scholar
• Chakravarti, S., C. A. Sabatos, S. Xiao, et al. 2005. Tim-2 regulates T helper type 2 responses and autoimmunity. J. Exp. Med. 202: 437–444
   PubMed Web of Science ®Google Scholar
• Lee, J., B. Phong, A. M. Egloff, and L. P. Kane. 2011. TIM polymorphisms – genetics and function. Genes. Immun. 12: 595–604
   Google Scholar
• Zhu, C., A. C. Anderson, A. Schubart, et al. 2005. The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity. Nat. Immunol. 6: 1245–1252
   PubMed Web of Science ®Google Scholar
• Lee, S. Y., and J. M. Goverman. 2013. The influence of T cell Ig mucin-3 signaling on central nervous system autoimmune diseases is determined by the effector function of the pathogenic T cells. J. Immunol. 190: 4991–4999
   Google Scholar
• Lee, J., J. M. Oh, J. W. Hwang, et al. 2011. Expression of human TIM-3 and its correlation with disease activity in rheumatoid arthritis. Scand. J. Rheumatol. 40: 334–340
   PubMed Web of Science ®Google Scholar
• Zhao, P., L. Xu, P. Wang, et al. 2010. Increased expression of human T-cell immunoglobulin- and mucin-domain-containing molecule-4 in peripheral blood mononuclear cells from patients with system lupus erythematosus. Cell. Mol. Immunol. 7: 152–156
   PubMed Web of Science ®Google Scholar
• Mizui, M., T. Shikina, H. Arase, et al. 2008. Bimodal regulation of T cell-mediated immune responses by TIM-4. Int. Immunol. 20: 695–708
   Google Scholar
• Santiago, C., A. Ballesteros, L. Martinez-Munoz, et al. 2007. Structures of T cell immunoglobulin mucin protein 4 show a metal-Ion-dependent ligand binding site where phosphatidylserine binds. Immunity 27: 941–951
   PubMed Web of Science ®Google Scholar
• Wahren-Herlenius, M., and T. Dorner. 2013. Immunopathogenic mechanisms of systemic autoimmune diseases. Lancet 382: 819–831
   PubMed Web of Science ®Google Scholar
• Cope, A. P., and M. Feldmann. 2004. Emerging approaches for the therapy of autoimmune and chronic inflammatory disease. Curr. Opin. Immunol. 16: 780–786
   PubMed Web of Science ®Google Scholar
• Chatenoud, L. 2006. Immune therapies of autoimmune diseases: are we approaching a real cure? Curr. Opin. Immunol. 18: 710–717
   PubMed Web of Science ®Google Scholar
• Heininger, K., G. Stoll, C. Linington, et al. 1986. Conduction failure and nerve conduction slowing in experimental allergic neuritis induced by P2-specific T-cell lines. Ann. Neurol. 19: 44–49
   Google Scholar
• Abe, Y., F. Kamachi, T. Kawamoto, et al. 2013. TIM-4 has dual function in the induction and effector phases of murine arthritis. J. Immunol. 191: 4562–4572
   PubMed Web of Science ®Google Scholar
• Albacker, L. A., S. Yu, D. Bedoret, et al. 2013. TIM-4, expressed by medullary macrophages, regulates respiratory tolerance by mediating phagocytosis of antigen-specific T cells. Mucosal. Immunol. 6: 580–590
   PubMed Web of Science ®Google Scholar
• Nurtanio, N., and P. C. Yang. 2011. Role of TIM-4 in innate or adaptive immune response. N. Am. J. Med. Sci. 3: 217–221
   Google Scholar
• Kobayashi, N., P. Karisola, V. Pena-Cruz, et al. 2007. TIM-1 and TIM-4 glycoproteins bind phosphatidylserine and mediate uptake of apoptotic cells. Immunity 27: 927–940
   PubMed Web of Science ®Google Scholar
• Rodriguez-Manzanet, R., M. A. Sanjuan, H. Y. Wu, et al. 2010. T and B cell hyperactivity and autoimmunity associated with niche-specific defects in apoptotic body clearance in TIM-4-deficient mice. Proc. Natl. Acad. Sci. USA 107: 8706–8711
   PubMed Web of Science ®Google Scholar
• Meyers, J. H., S. Chakravarti, D. Schlesinger, et al. 2005. TIM-4 is the ligand for TIM-1, and the TIM-1-TIM-4 interaction regulates T cell proliferation. Nat. Immunol. 6: 455–464
   PubMed Web of Science ®Google Scholar
• Li, L., L. Mo, H. Hao, et al. 2014. Flagellin modulates TIM4 expression in mast cells. Cell. Biol. Int. 38: 1330–1336
   Google Scholar
• Rennert, P. D. 2011. Novel roles for TIM-1 in immunity and infection. Immunol. Lett. 141: 28–35
   PubMed Web of Science ®Google Scholar
• Yamanishi, Y., M. Takahashi, K. Izawa, et al. 2012. A soluble form of LMIR5/CD300b amplifies lipopolysaccharide-induced lethal inflammation in sepsis. J. Immunol. 189: 1773–1779
   Google Scholar
• Murakami, Y., L. Tian, O. H. Voss, et al. 2014. CD300b regulates the phagocytosis of apoptotic cells via phosphatidylserine recognition. Cell. Death. Differ. 21: 1746–1757
   Google Scholar
• Meyers, J. H., C. A. Sabatos, S. Chakravarti, and V. K. Kuchroo. 2005. The TIM gene family regulates autoimmune and allergic diseases. Trends. Mol. Med. 11: 362–369
   PubMed Web of Science ®Google Scholar
• Albacker, L. A., P. Karisola, Y. J. Chang, et al. 2010. TIM-4, a receptor for phosphatidylserine, controls adaptive immunity by regulating the removal of antigen-specific T cells. J. Immunol. 185: 6839–6849
   Google Scholar
• Wong, K., P. A. Valdez, C. Tan, et al. 2010. Phosphatidylserine receptor Tim-4 is essential for the maintenance of the homeostatic state of resident peritoneal macrophages. Proc. Natl. Acad. Sci. USA 107: 8712–8717
   PubMedGoogle Scholar
• Rodriguez-Manzanet, R., J. H. Meyers, S. Balasubramanian, et al. 2008. TIM-4 expressed on APCs induces T cell expansion and survival. J. Immunol. 180: 4706–4713
   PubMedGoogle Scholar
• Liu, T., S. H. He, P. Y. Zheng, et al. 2007. Staphylococcal enterotoxin B increases TIM4 expression in human dendritic cells that drives naive CD4 T cells to differentiate into Th2 cells. Mol. Immunol. 44: 3580–3587
   PubMed Web of Science ®Google Scholar
• Cao, W., M. Ryan, D. Buckley, et al. 2011. Tim-4 inhibition of T-cell activation and T helper type 17 differentiation requires both the immunoglobulin V and mucin domains and occurs via the mitogen-activated protein kinase pathway. Immunology 133: 179–189
   Google Scholar
• Ji, H., Y. Liu, Y. Zhang, et al. 2014. T-cell immunoglobulin and mucin domain 4 (TIM-4) signaling in innate immune-mediated liver ischemia-reperfusion injury. Hepatology [Epub ahead of print]. doi: 10.1002/hep.27334
   Google Scholar
• Shim, J. A., E. S. Lee, B. Choi, and S. Sohn. 2013. The role of T cell immunoglobulin mucin domains 1 and 4 in a herpes simplex virus-induced Behcet's disease mouse model. Mediators. Inflamm. 2013;2013:903948
   Google Scholar
• Cai, P. C., L. H. Hu, T. P. Cui, et al. 2009. Association of TIM4 promoter polymorphism –1419G>A with childhood asthma in a Chinese Han population. Tissue Antigens 74: 11–16
   Google Scholar
• Qiu, S., Y. Du, X. Duan, et al. 2012. B cell immunity in allergic nasal mucosa induces T helper 2 cell differentiation. J. Clin. Immunol. 32: 886–895
   Google Scholar
• Yeung, M. Y., M. M. McGrath, M. Nakayama, et al. 2013. Interruption of dendritic cell-mediated TIM-4 signaling induces regulatory T cells and promotes skin allograft survival. J. Immunol. 191: 4447–4455
   PubMed Web of Science ®Google Scholar
• Rong, S., J. K. Park, T. Kirsch, et al. 2011. The TIM-1:TIM-4 pathway enhances renal ischemia-reperfusion injury. J. Am. Soc. Nephrol. 22: 484–495
   Google Scholar
• Xu, W. D., H. F. Pan, J. H. Li, and D. Q. Ye. 2013. MicroRNA-21 with therapeutic potential in autoimmune diseases. Expert Opin. Ther. Targets 17: 659–665
   PubMed Web of Science ®Google Scholar
• Krahling, S., M. K. Callahan, P. Williamson, and R. A. Schlegel. 1999. Exposure of phosphatidylserine is a general feature in the phagocytosis of apoptotic lymphocytes by macrophages. Cell Death Differ. 6: 183–189
   PubMed Web of Science ®Google Scholar
• Bouts, Y. M., D. F. Wolthuis, M. F. Dirkx, et al. 2012. Apoptosis and NET formation in the pathogenesis of SLE. Autoimmunity 45: 597–601
   PubMed Web of Science ®Google Scholar
• Fransen, J. H., J. H. Berden, C. M. Koeter, et al. 2012. Effect of administration of apoptotic blebs on disease development in lupus mice. Autoimmunity 45: 290–297
   PubMed Web of Science ®Google Scholar
• Toda, S., R. Hanayama, and S. Nagata. 2012. Two-step engulfment of apoptotic cells. Mol. Cell Biol. 32: 118–125
   PubMedGoogle Scholar
• Miyanishi, M., K. Segawa, and S. Nagata. 2012. Synergistic effect of Tim4 and MFG-E8 null mutations on the development of autoimmunity. Int. Immunol. 24: 551–559
   PubMedGoogle Scholar
• Sanmarti, R., V. Ruiz-Esquide, and M. V. Hernandez. 2013. Rheumatoid arthritis: a clinical overview of new diagnostic and treatment approaches. Curr. Top. Med. Chem. 13: 698–704
   PubMed Web of Science ®Google Scholar
• Quan, L. D., G. M. Thiele, J. Tian, and D. Wang. 2008. The development of novel therapies for rheumatoid arthritis. Expert Opin. Ther. Pat. 18: 723–738
   PubMed Web of Science ®Google Scholar
• Pan, H. F., N. Zhang, D. Q. Ye, and X. P. Li. 2010. Serum IL-17 level in systemic lupus erythematosus patients. J. Intern. Med. 267: 438; author reply 439
   Google Scholar
• Pan, H. F., D. Q. Ye, and X. P. Li. 2008. Type 17 T-helper cells might be a promising therapeutic target for systemic lupus erythematosus. Nat. Clin. Pract. Rheumatol. 4: 352–353
   PubMedGoogle Scholar
• Alghasham, A., and Z. Rasheed. 2014. Therapeutic targets for rheumatoid arthritis: progress and promises. Autoimmunity 47: 77–94
   PubMed Web of Science ®Google Scholar